

Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Jun 02, 2021

Source URL: <https://qa1.novartis.us/news/media-releases/novartis-kymriah-pivotal-trial-demonstrates-strong-response-rates-and-remarkable-safety-profile-relapsed-or-refractory-follicular-lymphoma-0>

List of links present in page

1. <https://qa1.novartis.us/news/media-releases/novartis-kymriah-pivotal-trial-demonstrates-strong-response-rates-and-remarkable-safety-profile-relapsed-or-refractory-follicular-lymphoma-0>